HHLA2 and TMIGD2: new immunotherapeutic targets of the B7 and CD28 families

Murali Janakiram, Jordan M. Chinai, Aimin Zhao, Joseph A. Sparano, Xingxing Zang

Research output: Contribution to journalArticle

19 Scopus citations


We and others recently discovered HHLA2 as a new B7 family member and transmembrane and immunoglobulin domain containing 2 (TMIGD2) as one of its receptors. Based on a new study we propose that HHLA2 may represent a novel immunosuppressive mechanism within the tumor microenvironment and hence could be a target for cancer therapy. TMIGD2 may be another therapeutic target.

Original languageEnglish (US)
Issue number8
Publication statusPublished - Aug 3 2015



  • B7 family
  • CD28 family
  • HHLA2
  • TMIGD2
  • angiogenesis
  • immunosuppression
  • immunotherapy
  • ligand
  • receptor
  • tumor microenvironment

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology

Cite this